Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus
By
- AMS
posted
Jun 08, 2021 01:49 PM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience
- AMS
Added Jul 09, 2020
Blog Entry
Rituximab monotherapy in mild pemphigus
- AMS
Added Oct 26, 2020
Blog Entry
Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris
- AMS
Added Jan 12, 2021
Blog Entry
Long-lasting treatment for moderate-severe depressed facial scars: skin and hair derived new autologous tissue filler with subcision
- AMS
Added Apr 06, 2020
Blog Entry
Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single center experience of 12 cases
- AMS
Added Feb 21, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic